Pharsight

1. List of Bijuva drug patents

Application	Filing Date	Opposition Party	Legal Status
EP19163006A	2022-09-22	Dr. Schön, Neymeyr & Partner Patentanwälte mbB	Granted and Under Opposition
EP19163006A	2022-09-21	Rieck, Markus	Granted and Under Opposition
EP12850845A	2022-03-09	Dr. Schön, Neymeyr & Partner Patentanwälte mbB	Granted and Under Opposition
EP12850845A	2022-03-09	Rieck, Markus	Granted and Under Opposition
EP12850845A	2022-03-09	Generics [UK] Limited	Granted and Under Opposition
EP13807188A	2022-01-14	Rieck, Markus	Revoked
EP13807121A	2019-12-23	Rieck, Markus	Revoked

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11529360	MAYNE PHARMA	Natural combination hormone replacement formulations and therapies	Nov, 2032 (9 years from now)

Do you want to check out BIJUVA patents from before 2022?

Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient

Market Authorisation Date: 28 October, 2018

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1 mg/100 mg	06 Jan, 2020	1	16 May, 2022	21 Nov, 2032	Eligible

Strength	Dosage	Availability
0.5MG;100MG	CAPSULE;ORAL	Discontinued
1MG;100MG	CAPSULE;ORAL	Prescription

BIJUVA family patents

United States

Australia

Japan

European Union

Canada

Korea, Republic of

Mexico

Brazil

Russia

Argentina

Israel

Spain

Poland

Croatia

Hungary

Portugal

South Africa

Lithuania

2. List of Doryx drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6958161	MAYNE PHARMA	Modified release coated drug preparation	Dec, 2022 (5 months ago)
US8715724	MAYNE PHARMA	Tabletting process	Feb, 2028 (4 years from now)
US9295652	MAYNE PHARMA	Controlled release doxycycline	Oct, 2034 (11 years from now)
US9511031	MAYNE PHARMA	Controlled release doxycycline	Oct, 2034 (11 years from now)
US9446057	MAYNE PHARMA	Controlled release doxycycline	Dec, 2034 (11 years from now)

Do you want to check out DORYX patents from before 2022?

Drugs and Companies using DOXYCYCLINE HYCLATE ingredient

Market Authorisation Date: 06 May, 2005

Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet

Dosage: TABLET, DELAYED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
75 mg and 100 mg	05 Feb, 2009	1	28 Dec, 2010	15 Dec, 2022	Eligible
150 mg	19 Dec, 2008	1		15 Dec, 2022	Extinguished
200 mg	19 May, 2014	1	19 May, 2016	15 Dec, 2022	Eligible
80 mg	01 Jul, 2015	1	29 Apr, 2016	15 Dec, 2022	Eligible
50 mg	05 Nov, 2015	1	23 May, 2016	03 Feb, 2028	Eligible
60 mg and 120 mg	28 Sep, 2017	1		23 Dec, 2034

Strength	Dosage	Availability
EQ 50MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 75MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 80MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 100MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 150MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 200MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 60MG BASE	TABLET, DELAYED RELEASE;ORAL	Discontinued
EQ 120MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription

DORYX family patents

United States

Australia

3. List of Fabior drug patents

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US10688071	February, 2015	Decision	Leon LOUPENOK
US10568859	April, 2014	Decision	Leon LOUPENOK

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10568859	MAYNE PHARMA	Topical foam composition	Feb, 2030 (6 years from now)
US10688071	MAYNE PHARMA	Topical foam composition	Feb, 2030 (6 years from now)
US8808716	MAYNE PHARMA	Topical foam composition	Feb, 2030 (6 years from now)

Do you want to check out FABIOR patents from before 2022?

Drugs and Companies using TAZAROTENE ingredient

Market Authorisation Date: 11 May, 2012

Treatment: Topical treatment of acne vulgaris in patients 12 years of age or older

Dosage: AEROSOL, FOAM;TOPICAL

Strength	Dosage	Availability
0.1%	AEROSOL, FOAM;TOPICAL	Prescription

FABIOR family patents

United States

Japan

Australia

Korea, Republic of

Poland

China

Spain

Brazil

Canada

Portugal

Israel

Singapore

South Africa

Chile

Mexico

Denmark

European Union

4. List of Lexette drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020407	MAYNE PHARMA	Corticosteroid containing foam compositions and method of manufacture thereof	Nov, 2036 (13 years from now)
US10857159	MAYNE PHARMA	Halobetasol foam composition and method of use thereof	Nov, 2036 (13 years from now)
US10857159 (Pediatric)	MAYNE PHARMA	Halobetasol foam composition and method of use thereof	May, 2037 (14 years from now)

Do you want to check out LEXETTE patents from before 2022?

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Aug 18, 2024

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Market Authorisation Date: 24 May, 2018

Treatment: For the topical treatment of plaque psoriasis in patients 18 years of age and older

Dosage: AEROSOL, FOAM;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.0005	28 Jan, 2021	1		30 Nov, 2036

Strength	Dosage	Availability
0.05%	AEROSOL, FOAM;TOPICAL	Prescription

LEXETTE family patents

United States

Korea, Republic of

China

Philippines

Brazil

Canada

Singapore

Mexico

Japan

Australia

European Union

Spain

Malaysia

5. List of Nextstellis drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7732430	MAYNE PHARMA	Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception	Mar, 2025 (1 year, 8 months from now)

Do you want to check out NEXTSTELLIS patents from before 2022?

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 15, 2026

Drugs and Companies using DROSPIRENONE; ESTETROL ingredient

NCE-1 date: 2025-04-15

Market Authorisation Date: 15 April, 2021

Treatment: Use by females of reproductive potential to prevent pregnancy

Dosage: TABLET;ORAL

Strength	Dosage	Availability
3MG;14.2MG	TABLET;ORAL	Prescription

NEXTSTELLIS family patents

European Union

Netherlands

United States

Canada

Spain

Germany

Austria

Denmark

Portugal

Hong Kong

Turkey

Poland

China

Yugoslavia

Brazil

Ukraine

Norway

Japan

New Zealand

Korea, Republic of

Belgium

Cyprus

Israel

Mexico

Australia

Costa Rica

Ecuador

South Africa

Luxembourg

Hungary

6. List of Sorilux drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629128	MAYNE PHARMA	Vitamin formulation	May, 2026 (2 years from now)
US8263580	MAYNE PHARMA	Vitamin formulation	May, 2028 (4 years from now)

Do you want to check out SORILUX patents from before 2022?

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Nov 5, 2022

Drugs and Companies using CALCIPOTRIENE ingredient

Market Authorisation Date: 06 October, 2010

Treatment: Use of a calcipotriene containing foam for the treatment of psoriasis; Use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 18 years and older; Use of calcipotriene...

Dosage: AEROSOL, FOAM;TOPICAL